(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 9.27% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Neogenomics's revenue in 2026 is $745,969,000.On average, 13 Wall Street analysts forecast NEO's revenue for 2026 to be $105,268,411,423, with the lowest NEO revenue forecast at $101,932,385,620, and the highest NEO revenue forecast at $109,747,696,655. On average, 13 Wall Street analysts forecast NEO's revenue for 2027 to be $115,820,774,074, with the lowest NEO revenue forecast at $111,502,951,450, and the highest NEO revenue forecast at $120,999,296,565.
In 2028, NEO is forecast to generate $126,861,430,901 in revenue, with the lowest revenue forecast at $122,043,595,041 and the highest revenue forecast at $132,685,803,820.